176 related articles for article (PubMed ID: 37318381)
41. Genome-Wide Plasma Cell-Free DNA Methylation Profiling Identifies Potential Biomarkers for Lung Cancer.
Xu W; Lu J; Zhao Q; Wu J; Sun J; Han B; Zhao X; Kang Y
Dis Markers; 2019; 2019():4108474. PubMed ID: 30867848
[TBL] [Abstract][Full Text] [Related]
42. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
43. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
44. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
[TBL] [Abstract][Full Text] [Related]
45. Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection.
Kim SY; Jeong S; Lee W; Jeon Y; Kim YJ; Park S; Lee D; Go D; Song SH; Lee S; Woo HG; Yoon JK; Park YS; Kim YT; Lee SH; Kim KH; Lim Y; Kim JS; Kim HP; Bang D; Kim TY
Exp Mol Med; 2023 Nov; 55(11):2445-2460. PubMed ID: 37907748
[TBL] [Abstract][Full Text] [Related]
46. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
[TBL] [Abstract][Full Text] [Related]
47. Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer.
Jang H; Choi CM; Lee SH; Lee S; Jeong MK
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361723
[TBL] [Abstract][Full Text] [Related]
48. Feasibility Analysis of Cell-Free DNA Derived from Plasma of Lung Cancer Patients for Next-Generation Sequencing.
Jiang X; Li H; Liu J; Sun H; Zhang L; Li W; Yao J; Cheng Y
Biopreserv Biobank; 2020 Apr; 18(2):117-121. PubMed ID: 32083487
[No Abstract] [Full Text] [Related]
49. Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network.
Deng Z; Ji Y; Han B; Tan Z; Ren Y; Gao J; Chen N; Ma C; Zhang Y; Yao Y; Lu H; Huang H; Xu M; Chen L; Zheng L; Gu J; Xiong D; Zhao J; Gu J; Chen Z; Wang K
Genome Med; 2023 Nov; 15(1):93. PubMed ID: 37936230
[TBL] [Abstract][Full Text] [Related]
50. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.
Bennett CW; Berchem G; Kim YJ; El-Khoury V
Oncotarget; 2016 Oct; 7(43):71013-71035. PubMed ID: 27589834
[TBL] [Abstract][Full Text] [Related]
51. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
[TBL] [Abstract][Full Text] [Related]
52. Sputum cell-free DNA for detection of alterations of multiple driver genes in lung adenocarcinoma.
Wang Z; Li L; Wang Y; Li X; Xu Y; Wang M; Liang L; Wu X; Tang M; Li Y; He S; Du J; He L; Sun M; Yang L; Di J; Gai F; Liu D
Cancer Cytopathol; 2023 Feb; 131(2):110-116. PubMed ID: 36103360
[TBL] [Abstract][Full Text] [Related]
53. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
[TBL] [Abstract][Full Text] [Related]
54. Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies.
Gao Q; Lin YP; Li BS; Wang GQ; Dong LQ; Shen BY; Lou WH; Wu WC; Ge D; Zhu QL; Xu Y; Xu JM; Chang WJ; Lan P; Zhou PH; He MJ; Qiao GB; Chuai SK; Zang RY; Shi TY; Tan LJ; Yin J; Zeng Q; Su XF; Wang ZD; Zhao XQ; Nian WQ; Zhang S; Zhou J; Cai SL; Zhang ZH; Fan J
Ann Oncol; 2023 May; 34(5):486-495. PubMed ID: 36849097
[TBL] [Abstract][Full Text] [Related]
55. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
56. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
57. Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies.
Magenheim J; Rokach A; Peretz A; Loyfer N; Cann G; Amini H; Moradi P; Nagaraju S; Sameer W; Cohen A; Fogel O; Kuint R; Abutbul A; Abu Rmeileh A; Karameh M; Cohen Goichman P; Wald O; Korach A; Neiman D; Fox-Fisher I; Moss J; Cohen D; Piyanzin S; Ben Ami R; Quteineh A; Golomb E; Shemer R; Glaser B; Kaplan T; Fridlender ZG; Dor Y
Eur Respir J; 2022 Nov; 60(5):. PubMed ID: 35450968
[TBL] [Abstract][Full Text] [Related]
58. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.
Liu MC; Oxnard GR; Klein EA; Swanton C; Seiden MV;
Ann Oncol; 2020 Jun; 31(6):745-759. PubMed ID: 33506766
[TBL] [Abstract][Full Text] [Related]
59. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
60. Aberrant Telomere Length in Circulating Cell-Free DNA as Possible Blood Biomarker with High Diagnostic Performance in Endometrial Cancer.
Benati M; Montagnana M; Danese E; Mazzon M; Paviati E; Garzon S; Laganà AS; Casarin J; Giudici S; Raffaelli R; Ghezzi F; Franchi M; Lippi G
Pathol Oncol Res; 2020 Oct; 26(4):2281-2289. PubMed ID: 32462419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
